© Copyright Bhekisisa - Centre for Health Journalism | Privacy Policy | Terms and Conditions | Bhekisisa PAIA Manual
OUR LATEST POSTS
TB talks: Will #UNGA78 change these three lives?
In the past five years, none of the targets political leaders adopted after the previous round of high-level discussions on the fight against tuberculosis (TB) at the United Nations General Assembly have been met. Today, talks will focus on how to get us back on track to end the disease by 2030.
#UNGA78: What the NHI means for universal health coverage in SA
The third day of high-level meetings at the 78th United Nations General Assembly is dedicated to talks on universal health coverage. In South Africa, this means talking about the proposed National Health Insurance fund — something that’s getting people hot under the collar. We’ve put together a one-stop page with information to support constructive debate.
#UNGA78: How SA’s mRNA hub is teaching the world about preparing for the next pandemic
We will see more pandemics like COVID in the future — which is why political leaders are convening in New York today at the United Nations first ever high-level meeting on pandemic preparedness. Being able to make vaccines locally can stop Africa having to be at the back of the queue waiting for medicines the next time round. Here’s how.
[WATCH] How anti-cervical cancer jabs work
Most cervical cancer cases are caused by the human papillomavirus (HPV), which spreads through sex. Anti-HPV injections have been around since 2006 and getting the jab as a teenager can stop cervical cancer in about nine out of 10 women later in life. We break down how they work, what they cost and why they save lives.
More bullying? J&J will be investigated for high TB drug prices and abuse of patent laws
South Africa’s Competition Commission will investigate the American drugmaker Johnson & Johnson for the high price it has been charging the country for the tuberculosis medicine bedaquiline, as well as for extending the tablets’ 20-year patent to block cheaper generics from entering the country.
R13 000 for a packet of pills to thwart long COVID. Is it worth it?
Up to one in five people can get long COVID — a condition in which someone keeps on feeling ill for months after their initial symptoms have cleared up. A drug called Paxlovid can lower the chance of developing the long-haul version of COVID. But at what cost?